Cox 2 Inhibitors Market to Witness Huge Growth by 2031 | Cadila Pharmaceuticals

Cox 2 Inhibitors are a type of non-steroidal anti-inflammatory drugs. These drugs are responsible for decreasing the production of prostaglandins.

These drugs also reduce the production of chemicals that play an important role in promoting fever, inflammatory pain etc.

To get in-depth information view the report @ https://www.factmr.com/report/3221/cox-2-inhibitors-market

Cyclooxygenase (Cox) is an enzyme, which is responsible for producing prostaglandins. The cyclooxygenase enzymes are of two types- cox 1 and cox 2. Cox 2 inhibitors, reduce the production of prostaglandins, hence, can reduce inflammatory pain, fever etc.

There are some of the safety issues, associated with cox 2 inhibitors, hence, they have been taken off from the U.S. market.

Also, many products have been recalled in the market. For example- Vioxx, which is a cox 2 inhibitor, was recalled worldwide in 2004 as it caused cardiovascular diseases such as heart attacks and heart strokes.

Bextra, which is another cox 2 inhibitor, was taken off from many European and U.S. markets in April 2005 due to cardiovascular risks and life-threatening skin reactions.

There are many such other products like Prexige, which was withdrawn from most of the world’s market because of the severe liver damage caused by this drug. There are many controversies ongoing, which are criticizing the use of cox 2 inhibitors.

Celecoxib is the only COX-2 inhibitor, which is currently available in the United States. There is a new approach to manufacturing natural Cox 2 inhibitors, which is being adopted by the company, Sabinsa.

Manufacture of natural Cox 2 inhibitors have very fewer side effects and is expected to be highly adopted by the people.

Know the COVID-19 Impact on Europe Region, Request for Sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=3221

The high adoption rate of cox 2 inhibitors, such as aspirin pain killer, is one of the major factors, driving the growth of cox 2 inhibitors market. The increasing prevalence of chronic diseases, such as rheumatoid arthritis, osteoarthritis, and other diseases, is expected to increase the growth of cox 2 inhibitors market.

Increasing awareness of physical activities can lead to sports injury, which can also be expected to drive the cox 2 inhibitors market.

The cox 2 inhibitors have many safety issues, hence, some of the cox 2 inhibitors have been withdrawn from the U.S. market. For example- Arcoxia is a cox 2 inhibitor, which is present in many countries but not in U.S. Dynastat is another cox 2 inhibitors, which is a form of injectable medicine and is not available in the U.S. market.

The safety issues, associated with cox 2 inhibitors, can restrain the growth of cox 2 inhibitors market. Intake of cox 2 inhibitors, can also cause gastrointestinal problems for the people, which decreases the demand of ox 2 inhibitors, hence, can hamper the growth of the overall market.

Other side effects, such as headache, migraine, nausea, also decreases the demand for cox 2 inhibitors.

Share Your Requirements & Get Customized Reports @ https://www.factmr.com/connectus/sample?flag=RC&rep_id=3221

The global Cox 2 Inhibitors market is segmented on the basis of product type, Indication, distribution channel, and geography:

Segmentation by Product type
Selective Cox 2 Inhibitors
Non Selective Cox 2 Inhibitors
Segmentation by Indication
Osteoarthritis
Rheumatoid Arthritis
Menstrual Cramps
Sports Injuries
Others
Segmentation by distribution channels
Hospital Pharmacies
Drug stores
Retail pharmacies

Based on the product type, the Cox 2 Inhibitors are segmented into selective cox 2 inhibitors and non- selective cox 2 inhibitors. Selective Cox 2 inhibitors are generally used for the treatment of osteoarthritis and rheumatoid arthritis.

Selective Cox 2 inhibitors are expected to hold the largest revenue share in Cox 2 Inhibitors market. Non Selective Cox 2 inhibitors include drugs such as aspirin, ibuprofen etc. Basically, Cox 2 inhibitors are used to treat inflammatory pain.

Based on the indication, the Cox 2 inhibitors market has been segmented into indication such as osteoarthritis, rheumatoid arthritis, menstrual cramps etc. Based on the end user, the market has been segmented into hospital pharmacies, drug stores, retail pharmacies.

Drug stores are expected to show the maximum sales of Cox 2 inhibitors and can hold a large revenue share in the market.

Pre-Book Now for Exclusive Analyst Support @ https://www.factmr.com/checkout/3221/S

Geographically, global Cox 2 Inhibitors market has been divided into few regions, such as North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. North America is expected to dominate the cox 2 inhibitors global market due to the presence of high research and developmental activities.

Europe is expected to hold the second largest share in the global Cox 2 Inhibitors market due to the presence of high population and high prevalence of rheumatoid arthritis.

The Asia Pacific is expected to hold a large share in the cox 2 inhibitors market because of the presence of more number of people preferring inflammatory pan medicines.

There are only a few companies, such as Cadila Pharmaceuticals, which are manufacturing cox 2 inhibitors. Sabinsa manufactures natural herbal drugs and is focusing on manufacturing natural Cox 2 inhibitors.

Visit Our Website: https://www.factmr.com
Research Insight: https://www.factmr.com/report/3221/cox-2-inhibitors-market

Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.

This release was published on openPR.